PRDM10-rearranged Soft Tissue Tumor: A Clinicopathologic Study of 9 Cases.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 21 12 2018
medline: 14 1 2020
entrez: 21 12 2018
Statut: ppublish

Résumé

Gene fusion transcripts containing PRDM10 were recently identified in low-grade undifferentiated pleomorphic sarcomas (UPS). Here, we describe the morphologic and clinical features of 9 such tumors from 5 men and 4 women (age: 20 to 61 y). Three cases had previously been diagnosed as UPS, 3 as superficial CD34-positive fibroblastic tumor (SCD34FT), 2 as pleomorphic liposarcoma, and 1 as pleomorphic hyalinizing angiectatic tumor. The tumors were located in the superficial and deep soft tissues of the thigh/knee region (4 cases), shoulder (2 cases), foot, trunk, and perineum (1 case each) ranging in size from 1 to 6 cm. All showed poorly defined cellular fascicles of pleomorphic cells within a fibrous stroma with frequent myxoid change and a prominent inflammatory infiltrate. All displayed highly pleomorphic nuclear features, but a low mitotic count. Most tumors were well circumscribed. One of 9 tumors recurred locally, but none metastasized. Immunohistochemically, all were CD34 and showed nuclear positivity for PRDM10; focal positivity for cytokeratins was seen in 5/6 cases. PRDM10 immunoreactivity was evaluated in 50 soft tissue tumors that could mimic PRDM10-rearranged tumors, including 4 cases exhibiting histologic features within the spectrum of SCD34FT. Except for 2/6 pleomorphic liposarcomas and 1/4 myxofibrosarcomas, other tumors did not show nuclear positivity but displayed weak to moderate cytoplasmic immunoreactivity. In conclusion, PRDM10-rearranged soft tissue tumor is characterized by pleomorphic morphology and a low mitotic count. Its morphologic spectrum overlaps with SCD34FT. Clinical features of this small series suggest an indolent behavior, justifying its distinction from UPS and other sarcomas.

Identifiants

pubmed: 30570551
doi: 10.1097/PAS.0000000000001207
doi:

Substances chimiques

DNA-Binding Proteins 0
PRDM10 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

504-513

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Auteurs

Florian Puls (F)

Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg.

Nischalan Pillay (N)

Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore.
Research Department of Pathology, University College London Cancer Institute, London.

Henrik Fagman (H)

Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg.

Anne Palin-Masreliez (A)

Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg.

Fernanda Amary (F)

Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore.

Magnus Hansson (M)

Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg.

Lars-Gunnar Kindblom (LG)

Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg.

Tom A McCulloch (TA)

Department of Histopathology, Nottingham City Hospital, Nottingham.

George Meligonis (G)

Department of Histopathology, Addenbrooke's Hospital, Cambridge.

Ronald Muc (R)

Department of Histopathology, Heartlands Hospital, Birmingham.

Pehr Rissler (P)

Department of Clinical Genetics and Pathology, University and Regional Laboratories, Skåne University Hospital, Lund University.

Vaiyapuri P Sumathi (VP)

Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK.

Roberto Tirabosco (R)

Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore.

Jakob Hofvander (J)

Department of Clinical Genetics, Lund University, Lund, Sweden.

Linda Magnusson (L)

Department of Clinical Genetics, Lund University, Lund, Sweden.

Jenny Nilsson (J)

Department of Clinical Genetics, Lund University, Lund, Sweden.

Adrienne M Flanagan (AM)

Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore.
Research Department of Pathology, University College London Cancer Institute, London.

Fredrik Mertens (F)

Department of Clinical Genetics and Pathology, University and Regional Laboratories, Skåne University Hospital, Lund University.
Department of Clinical Genetics, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH